Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: Results from a randomized, phase II prospective trial

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 448-453

  Mesia R ^a   Rueda, A ^b   Vera, R ^c   Lozano, A ^a   Medina, J A ^b   Aguiar, D ^d   arias F ^c   Triana, G ^e   Carles, J ^f   Lopez lopez R ^g  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c Universidad Pública de Navarra   (Spain)

^d HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^e Hospital Oncologico de Galicia   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Bioradiotherapy; Cetuximab maintenance; Oropharynx carcinoma

Indexed keywords

CETUXIMAB;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IATROGENIC DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; ODYNOPHAGIA; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DERMATITIS; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA;

EID: 84873825096     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds291     Document Type: Article

References (22)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
2. Goldstain NI, Prewett M, Zuklys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-1318.
3. Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999; 18: 427-436.
4. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940.
5. Huang SM, Harari PM. Modulation of radiation response following epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin Cancer Res 2000; 6: 2166-2174.
6. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
7. Pueyo G, Mesía R, Figueras A et al. Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy. Oncologist 2010; 15: 976-986.
8. Milas L, Fu-Ming F, Mason KA. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated raditain. Int J Radiation Oncology Phys 2007; 67: 568-572.
9. Peters LJ. Accelerated fractionation using the concomitant boost: a contribution of radiobiology to radiotherapy. Br J Radiol 1992; 24: 200-203.
10. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7-16.
11. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
12. Brandwein MS, Nuovo GJ, Biller H. Analysis, of prevalence of human papillomavirus in laryngeal carcinomas. Study of 40 cases using polymerase chain reaction and consensus primers. Ann Otol Rhinol Laryngol 1993; 102: 309-313.
13. Kleter B, van Doorn LJ, ter Schegget J et al. A novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998; 153: 1731-1739.
14. Common Terminology Criteria for Adverse Events (CTCAE). v3.0. U.S. National Institute of Health. 2006; www.cancer.gov.
15. Argiris A, Heron DE, Smith RP et al. Induction docetaxel, cisplatin and cetuximab followed by concurrent radiotherapy, cisplatin and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 2010; 28: 5294-5300.
16. Vermorken J, Mesía R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
17. Hitt R, López-Pousa A, Martínez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636-8645.
18. Vermorken JB, Remenar E, van Harpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
19. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
20. Gibson MK, Li Y, Murphy B et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562-3567.
21. Grau JJ, Caballero M, Verger E et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2009; 129: 1294-1299.
22. Hitt R, Irigoyen A, Cortés-Funes H et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2012; 23: 1016-1022